BioSig Technologies, Inc. — Q1 2015 Form 10-Q
Entity note: The request metadata names Streamex Corp., but the supplied filing is for BioSig Technologies, Inc. The filing covers the three months ended March 31, 2015; financial statements are unaudited.
Business context and reporting period
BioSig is developing the PURE EP System, a cardiac recording and analysis platform for electrophysiology procedures. It had no commercial products, customers, or revenue during the quarter. The company reported its first animal study using the prototype at Mayo Clinic on March 31, 2015 and said it was planning further studies and FDA 510(k) work.
Financial performance and liquidity
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $302,079 | $122,151 |
| General and administrative | $2,746,853 | $601,565 |
| Total operating expenses | $3,051,792 | $728,151 |
| Net loss per financial statements | $3,052,906 | $1,117,534 |
| Cash used in operating activities | $1,219,982 | $505,763 |
| Cash at quarter-end | $2,059,328 | $5,365 at March 31, 2014 |
There are no meaningful revenue or gross-margin measures because the company has not begun generating revenue. Operating expenses increased substantially, particularly G&A, which management attributed mainly to stock-based compensation, higher payroll, and consulting and investor-relations costs. The filing reports $2,054,475 of stock-based compensation in the MD&A discussion; the cash-flow statement reports $1,634,714 of equity-based compensation, a difference investors should reconcile.
Working capital was negative $4,544,839. Current liabilities were $6,763,935, including $4,097,444 of warrant liability and $1,242,590 of derivative liability. These fair-value liabilities were newly recognized after the company concluded a market for its common stock had been established; they are Level 3 valuations, not conventional funded debt. The company reported no convertible debentures outstanding. Q1 financing provided $3,042,213 from common-stock sales. Stockholders’ deficit was $6,967,995 at March 31, 2015.
Material changes, outlook, and risks
- Operating expenses rose from $728,151 to $3,051,792 year over year; R&D increased 147.3% and G&A increased 357% according to management.
- The company raised net proceeds of $3,042,213 during the quarter through common-stock sales, with warrants issued alongside the shares. Common shares outstanding increased to 13,159,694 from 11,179,266 at year-end 2014.
- Management said it expects losses and negative operating cash flow to continue and estimated it would need approximately $1 million in addition to available cash to fund operating expenses and capital equipment for the next 12 months. It stated existing cash would not be sufficient for those needs.
- Management targeted FDA 510(k) marketing clearance in the first half of 2016, subject to financing, regulatory approvals, and successful development and studies. This is a stated expectation, not a guarantee.
- The filing repeats the auditor’s substantial-doubt going-concern warning. Continued operations depend on obtaining additional financing; failure to do so could delay, reduce, or end development. Further equity financing may dilute shareholders.
- Series C preferred stock has redemption triggers, including certain judgments and bankruptcy proceedings. A triggered redemption could require cash or shares, and the company cautions it may be unable to meet the obligation.
- Management concluded disclosure controls were effective at a reasonable assurance level and reported no material changes in internal control over financial reporting. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is BioSig Technologies, Inc., not Streamex Corp.
- Reconcile the MD&A’s reported net loss of $3,090,801 with the financial statements’ net loss of $3,052,906 and net loss available to common stockholders of $3,132,301.
- Reconcile the MD&A stock-based compensation figure of $2,054,475 with the cash-flow statement’s $1,634,714 equity-based compensation figure.
- Assess cash runway, the stated additional $1 million funding need, and the company’s ability to raise capital on acceptable terms.
- Review the assumptions and potential effects of the $5,340,034 warrant and derivative liabilities, Series C redemption provisions, and outstanding options and warrants.
- Track prototype testing, clinical-study plans, FDA submission milestones, and whether the first-half 2016 clearance expectation remains achievable.